Channelopathies in Heart Disease
The book “Channelopathies in Heart Disease” provides a translational overview of current state-of-the art research on ion channel (dys)function, cardiac channelopathies, and inherited arrhythmia syndromes. The latest insight on the structure and function of cardiac ion channels and the pro-arrhythmic consequences of their dysfunction is presented. Clinical and genetic characteristics of various inherited channelopathies and arrhythmia syndromes are discussed, in addition to new technologies available to this translational research field.
KeywordsArrhythmogenesis Atrial fibrillation Electrophysiology Genetics Ion channel Ventricular arrhythmia
Compliance with Ethical Standards
Sources of Funding
This work was funded by a Priority Medicines Rare Diseases and Orphan Drugs grant (PM-Rare, 113303006 to C.A.R.) from The Netherlands Organization for Health Research and Development (ZonMw) and an Innovational Research Incentives Scheme Vidi grant from ZonMw (grant no. 91714371 to C.A.R.), by the German Cardiac Society and the Hengstberger Foundation (Klaus-Georg and Sigrid Hengstberger Scholarship to D.T.), the German Heart Foundation/German Foundation of Heart Research (F/08/14 to D.T.), the Joachim Siebeneicher Foundation (to D.T.), and the Baden-Wuerttemberg Ministry of Science, Research and Art (Sonderlinie Medizin to D.T.).
Conflict of Interest
C.A.R. has previously received research grants from Gilead Sciences. D.T. reports receiving lecture fees/honoraria from Bayer Vital, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Medtronic, Pfizer Pharma, Sanofi-Aventis, St. Jude Medical, and ZOLL CMS and research grant support from Daiichi Sankyo. D.T. filed a patent application for the use of K2P potassium channels for altering cardiac electrophysiology.
This article does not contain any studies with human participants or animals performed by any of the authors.